Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL

This study is testing a new type of CAR-T cell therapy — a treatment where your own immune cells are engineered to attack cancer — for people with a hard-to-treat blood cancer called T-cell leukemia or lymphoma that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 3 and 70 years old - You have been diagnosed with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma - You are in reasonably good physical condition (ECOG 0-2) - You are expected to live at least 12 weeks **You may NOT be eligible if...** - You have severe organ problems (heart, liver, kidney, or lung) - You have an active, uncontrolled infection - You are pregnant or breastfeeding - You have received certain prior CAR-T therapies Talk to your doctor to see if this trial is right for you.